Health-related quality of life in the randomized phase 3 study of ramucirumab plus docetaxel versus placebo plus docetaxel in platinum-refractory advanced urothelial carcinoma (RANGE)

Table 2 EORTC QLQ-C30 and EQ-5D-5L compliance rates from baseline through cycle 8 and 30-day follow-up (ITT population)

DOC docetaxel, EORTC QLQ-C30 European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30, EQ-5D-5L EuroQoL five-dimensions, ITT intention-to-treat, PL placebo, RAM ramucirumab
Data are presented as number/total number (%)
For compliance, the total number is the number expected to complete at the assessment time point
On-treatment compliance reporting is truncated at cycle 8, but similar rates were reported for later cycles
The median number of cycles administered in both treatment arms was 4

ISSN: 1471-2490